✨ Free AI Report
GlycoMimetics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research GlycoMimetics, Inc.
Company Research

GlycoMimetics, Inc.: Business Overview, Financials & Competitive Analysis

GlycoMimetics, Inc. scores 4/10 on the AskCyborg Cyborg Score (Challenged). Post-merger turnaround play dependent on execution of Crescent's oncology pipeline with new investor backing through 2027. The Phase 2 analysis of uproleselan did not achieve its primary endpoint in a trial evaluating the drug in combination with chemotherapy versus chemotherapy alone in newly diagnosed AML patients, failing to demonstrate statistically.

What is GlycoMimetics, Inc.'s industry? GlycoMimetics, Inc. (glycomimetics.com) operates in Biotechnology - Clinical Stage / Specialty Oncology. AskCyborg classifies GlycoMimetics, Inc. under Biotechnology - Clinical Stage / Specialty Oncology in its company registry.

GlycoMimetics operates in the biotechnology sector, focusing on the development of glycomimetic drugs that inhibit carbohydrate-protein interactions for the treatment of various medical conditions. The company underwe...

4/ 10Challenged

Cyborg Score thesis

Post-merger turnaround play dependent on execution of Crescent's oncology pipeline with new investor backing through...

Read the full analyst-debate transcript →
Industry Biotechnology - Clinical Stage / Specialty Oncology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 5, 2026
AI-Verified Research
30+ Page Report

Get the Latest GlycoMimetics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for GlycoMimetics, Inc.

AskCyborg analysts argue the bull and bear cases for GlycoMimetics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
GlycoMimetics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

GlycoMimetics, Inc. Overview

Pro stress-test →

GlycoMimetics operates in the biotechnology sector, focusing on the development of glycomimetic drugs that inhibit carbohydrate-protein interactions for the treatment of various medical conditions. The company underwent a transformational merger with Crescent Biopharma in June 2025, rebranding as Crescent Biopharma (CBIO) and pivoting to solid tumor immunotherapy programs.

Strategic Profile

Pro stress-test →

GlycoMimetics announced an acquisition agreement with Crescent Biopharma, with the combined company operating as Crescent Biopharma, backed by a $200 million financing, with the transaction closing in Q2 2025. The company will advance Crescent's portfolio, including CR-001, a tetravalent PD-1 x VEGF bispecific antibody with preliminary proof of concept data expected in 2H26.

Competitive Landscape

Pro stress-test →

In immuno-oncology/solid tumors, Crescent competes with major bispecific antibody developers including Genmab, Regeneron (REGN), and Incyte. Prior AML focus positioned against Agios, Celgene/Bristol Myers, and Gilead. The bispecific antibody space is increasingly crowded with established players (Roche, Pfizer, Johnson & Johnson) and emerging biotech competitors.

Industry Context

GlycoMimetics, Inc. operates in Biotechnology - Clinical Stage / Specialty Oncology.

Key facts

Founded: 2003 · Headquarters: Rockville, US

What the analysts stress-tested

The top findings that survived the multi-agent debate for GlycoMimetics, Inc..

  • Completed transformational merger with Crescent Biopharma (June 2025); entity now operates as Crescent Biopharma under ticker CBIO
  • Lead AML program (uproleselan) failed Phase 2 primary endpoint; strategic pivot to solid tumor immunotherapy via Crescent acquisition
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • June 2025GlycoMimetics merges with Crescent Biopharma; company rebranded as Crescent Biopharma trading as CBIO on NASDAQ
  • December 2024Clinical data on uproleselan presented at ASH Annual Meeting for AML indications
  • +1 moreTrack every material event for GlycoMimetics, Inc. as it happens. Explore monitoring →
Get alerted when GlycoMimetics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

FabhaltaFactor D inhibitor for AML→Venetoclax combinationsStandard-of-care AML therapy→Bispecific antibodiesCompeting immuno-oncology platforms→

Compare GlycoMimetics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

GlycoMimetics, Inc. operates in Biotechnology - Clinical Stage / Specialty Oncology. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Clinical Stage / Specialty Oncology research →
NEW · MCP server

Ask your AI assistant about GlycoMimetics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare GlycoMimetics, Inc. and its top competitor on Cyborg Score”
“What did GlycoMimetics, Inc. do this quarter?”
“Is GlycoMimetics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does GlycoMimetics, Inc. do?+
GlycoMimetics operates in the biotechnology sector, focusing on the development of glycomimetic drugs that inhibit carbohydrate-protein interactions for the treatment of various medical conditions. The company underwe...
What is GlycoMimetics, Inc.'s Cyborg Score?+
GlycoMimetics, Inc. has a Cyborg Score of 4/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are GlycoMimetics, Inc.'s main competitors?+
Named competitors include Fabhalta, Venetoclax combinations, Bispecific antibodies. The full competitive landscape is in the AskCyborg report.
How can I get the full GlycoMimetics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the GlycoMimetics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track GlycoMimetics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.